Chrysanthemum: Antioxidants and Heart Health

This is the claim where chrysanthemum has the best data and the weakest conclusion, and the two facts are not in tension — they are the whole story. What is in the cup is genuinely well characterised. Published HPLC analyses of Chrysanthemum morifolium flower teas have quantified the flavones (luteolin, apigenin, acacetin and their glucosides) and the phenolic acids (chlorogenic acid, 3,5-dicaffeoylquinic acid) with real precision, and shown that cultivar and flower colour measurably change the profile. The infusion scores highly on every standard chemical antioxidant assay.

What none of that establishes is a health outcome. There is no adequately powered randomized controlled trial showing that chrysanthemum tea lowers blood pressure, improves lipids, changes vascular function, or reduces cardiovascular events in humans. The mechanism literature is broad and interesting and entirely preclinical. This page explains what the antioxidant numbers actually measure, why "high antioxidant capacity" has repeatedly failed to predict health outcomes, what the traditional blood-pressure indication really says, and what the honest comparison with hibiscus — a floral tea that does have randomized trials — looks like.

Species, as always: Chrysanthemum morifolium is the tea flower. Chrysanthemum indicum (ye ju hua) is a separate, more bitter pharmacopoeial herb with a different use profile and different chemistry. Tanacetum cinerariifolium — pyrethrum, formerly classified in Chrysanthemum — is the insecticide plant and is not a tea.

Table of Contents

  1. What Is Actually in the Cup
  2. What DPPH, ABTS and FRAP Really Measure
  3. Why "High Antioxidant" Stopped Being a Health Claim
  4. The Bioavailability Problem
  5. Brewing and Flower Quality Dominate the Polyphenol Content
  6. Blood Pressure: the Traditional Claim and the Missing Trial
  7. The Hibiscus Comparison
  8. Chlorogenic Acid: the One Constituent With Human Data
  9. Lipids, Platelets and Endothelial Function
  10. The Sugar in the Can Is the Real Cardiovascular Variable
  11. Medication Interactions and Who the Research Raises Concerns For
  12. The Verdict
  13. Key Research Papers
  14. Connections
  15. Featured Videos

What Is Actually in the Cup

Evidence tier: well established (analytical chemistry). This is the one part of chrysanthemum's profile where the numbers are solid, because measuring compounds is a much easier problem than measuring outcomes.

Han and colleagues, in “Phytochemical composition and antioxidant activities of two different color chrysanthemum flower teas” in Molecules (2019), did the useful thing of analysing the flowers as a tea rather than as a solvent extract, and reported both the phenolic profile and the antioxidant assay results with the cultivars distinguished. The same group's earlier work in the International Journal of Analytical Chemistry (2017) quantified phenolics in a new cultivar by HPLC with diode-array detection and mass spectrometry. These are the papers to read if you want to know what your cup contains, and their most important collective finding is variability — "chrysanthemum tea" is not one defined substance.

What DPPH, ABTS and FRAP Really Measure

Chrysanthemum infusions perform well on the standard chemical antioxidant assays. It is worth knowing exactly what those assays do, because the gap between what they measure and what readers assume they measure is where most "superfood" marketing lives.

All four are chemistry, performed in a test tube, in the absence of a body. A high score tells you an extract contains reducing compounds. It says nothing about whether those compounds are absorbed, whether they survive gut and liver metabolism, whether they reach any relevant tissue, whether their metabolites retain activity, or whether reducing that tissue's oxidative load would improve anything. It is a compositional fact.

Two sanity checks make the point better than any argument. Coffee, red wine and dark chocolate all score extremely highly. So do many things nobody proposes eating. And the ranking of foods by antioxidant assay has never lined up with the ranking of foods by measured health outcome in cohort studies or trials.

So when a chrysanthemum product's marketing quotes a DPPH or oxygen radical absorbance capacity figure, the correct response is not scepticism about the number — the number is probably accurate — but recognition that the number is not the kind of thing that can support a health claim.

Why "High Antioxidant" Stopped Being a Health Claim

This deserves its own section because it is the single most useful piece of context a reader can have when evaluating any polyphenol-rich food.

The oxidative-stress hypothesis of chronic disease was a serious, well-motivated idea: reactive oxygen species damage lipids, proteins and DNA; that damage accumulates; therefore supplementing antioxidants should slow disease. It generated an enormous amount of research and a very large consumer market. And then it was tested in humans, at scale, in randomized trials, and it largely failed.

The pattern across large antioxidant supplement trials was consistent and sobering. High-dose beta-carotene trials in smokers found increased lung cancer incidence rather than decreased. Large vitamin E trials for cardiovascular prevention found no benefit, and pooled analyses raised concerns at high doses. A major prostate-cancer prevention trial of vitamin E and selenium found no benefit and a signal of harm in one arm. Antioxidant vitamin combinations for cardiovascular prevention have repeatedly come out neutral.

Why it failed matters, because the reasons apply directly to chrysanthemum:

  1. Reactive oxygen species are signalling molecules, not just damage. They mediate insulin sensitivity, exercise adaptation, immune killing of pathogens and apoptosis of damaged cells. Blanket suppression is not obviously desirable, and some of the trial harms are best explained this way.
  2. The body has its own layered antioxidant machinery — superoxide dismutase, catalase, glutathione peroxidase, the thioredoxin system — which is regulated, localised and vastly more consequential than a few milligrams of dietary reductant.
  3. The interesting effects of polyphenols probably are not antioxidant effects at all. Current thinking leans toward polyphenols acting as mild stressors that upregulate the body's own defences (the Nrf2 pathway), or as modulators of signalling, enzymes and the gut microbiome. If so, their in-vitro radical-scavenging score is close to irrelevant to how they actually work.
  4. Whole foods are not their extracts. Cohort studies associating polyphenol-rich diets with better outcomes cannot be reduced to a supplement, and when they have been, the supplement usually fails.

The honest conclusion for chrysanthemum: its high antioxidant assay score is a true statement about the extract and a very weak basis for expecting a health benefit. It belongs in the "interesting chemistry" column, not the "reason to drink it medicinally" column.

The Bioavailability Problem

Even setting aside whether antioxidant activity is the right mechanism, there is a quantitative gap between the in-vitro work and a cup of tea that is rarely stated plainly.

The dose. Five to ten dried flower heads is roughly 1–3 g of dried flower. Depending on cultivar, grade and brewing, that delivers on the order of tens of milligrams of total phenolics, of which the flavones are a minority fraction — a few milligrams of mixed luteolin, apigenin and acacetin derivatives, spread across a whole adult.

The absorption. Flavone glycosides are hydrolysed in the gut, absorbed modestly, and then extensively conjugated — glucuronidated and sulphated — in the enterocyte and the liver before they ever reach systemic circulation. Plasma concentrations of free aglycone after a dietary dose are typically in the low nanomolar to sub-micromolar range. Much of the ingested polyphenol never gets absorbed at all and is instead metabolised by colonic bacteria into a wholly different set of small phenolic compounds, which are increasingly suspected of being where the real biology happens.

The in-vitro concentrations. Cell-culture experiments demonstrating NF-κB suppression, nitric-oxide reduction or vasorelaxation typically use micromolar to tens-of-micromolar concentrations of pure aglycone applied directly to cells — often one to three orders of magnitude above achievable plasma levels of the free compound, and in a chemical form that circulating metabolites do not match.

This is not a nitpick, it is the central issue. Any sentence of the form "chrysanthemum contains luteolin, which does X in cells, therefore chrysanthemum tea does X in you" fails at this step. It is the same gap that has sunk countless promising nutraceutical mechanisms, and honest reading of the chrysanthemum literature requires holding it in mind on every claim.

Brewing and Flower Quality Dominate the Polyphenol Content

An underappreciated practical point: the variation introduced by which flowers you bought and how you brewed them is larger than any subtlety of pharmacology being argued about.

Factors that measurably change what is in your cup:

The practical upshot: whole intact flower heads of a named cultivar, stored dark and dry, keep their flavones and volatile oil best, and a short, hot steep extracts them with less bitterness than a long boil. No human health outcome has ever been shown to depend on any of these choices.

Blood Pressure: the Traditional Claim and the Missing Trial

Evidence tier: traditional use only, with preliminary mechanism. No adequately powered human trial.

Chrysanthemum is a genuine classical herb for what a modern reader would call hypertension — but it arrives there by a different route than a modern diagnosis. The relevant traditional action is "calms liver yang" (平肝), addressing a pattern of throbbing headache, dizziness, flushed face, irritability, tinnitus and red eyes. That symptom cluster overlaps substantially with how hypertension classically presented in clinic before routine measurement existed, which is why chrysanthemum appears in Chinese antihypertensive formulas and in Chinese dietary-therapy recommendations. Zou P's “Traditional Chinese medicine, food therapy and hypertension control: a narrative review of Chinese literature” in the American Journal of Chinese Medicine (2016) surveys that territory and lists chrysanthemum among the commonly used items.

Proposed mechanisms from preclinical work — each real as a laboratory finding, each a weak predictor of clinical effect:

There is no adequately powered, well-designed randomized controlled trial demonstrating that chrysanthemum tea lowers blood pressure in humans. Not in hypertensive patients, not in healthy volunteers, not acutely, not over weeks. You can check with a PubMed search for chrysanthemum blood pressure randomized trials.

What this means in practice:

  1. The tea is caffeine-free, a small difference from coffee for blood pressure, because caffeine has its own acute blood-pressure effect.
  2. The tea has never been tested as a replacement for antihypertensive medication. Uncontrolled hypertension is silent and its consequences — stroke, heart failure, kidney disease — are not.
  3. Home measurement — a validated upper-arm monitor, seated, rested, same time of day, several readings averaged — is how a person finds out what is actually happening to their blood pressure, and it tells far more than any herbal choice.
  4. The measures with trial evidence measured in millimetres of mercury and in prevented events are sodium reduction, potassium-rich whole foods, weight, alcohol, physical activity, treatment of sleep apnoea, and taking prescribed medication consistently. See Hypertension.

The Hibiscus Comparison

The most useful thing that can be said about chrysanthemum's blood-pressure claim is a comparison, because it shows what the evidence looks like when it exists.

Hibiscus (Hibiscus sabdariffa, roselle) is also a floral tea, also polyphenol-rich, also traditionally used for blood pressure. But hibiscus has been through multiple randomized controlled trials in humans. A 2022 meta-analysis of 17 trials (Ellis et al., Nutrition Reviews) found hibiscus lowered systolic blood pressure by 7.10 mmHg more than placebo, with the largest drops in people whose blood pressure was raised at the start, and lowered blood pressure about as much as the medicines it was compared with. A 2025 overview and updated meta-analysis (Norouzzadeh et al., Complementary Therapies in Medicine) of 26 randomized trials with 1,797 people found hibiscus lowered systolic and diastolic blood pressure in a dose-dependent way, with no significant difference from antihypertensive drugs; it noted a minor, clinically insignificant rise in the liver enzyme aspartate aminotransferase without more adverse events. The trials are mostly small and their results vary widely. But they exist, they were prespecified, they measured blood pressure with instruments, and they can be criticised on their methods rather than on their absence.

That is the contrast. Two floral teas with similar traditional claims and similar chemistry classes; one has been tested and shows a measurable effect, the other has not been tested at all. If someone tells you chrysanthemum lowers blood pressure "like hibiscus", the correct answer is that hibiscus earned that sentence and chrysanthemum has not.

It also illustrates a useful general point: a real, measured effect looks nothing like a marketing claim. The hibiscus literature's honest summary is a drop of several mmHg, largest in people with raised blood pressure, from trials of variable quality — which is exactly the sort of unglamorous finding that a genuine effect produces, and exactly the sort of finding chrysanthemum does not have.

Chlorogenic Acid: the One Constituent With Human Data

There is one thread of the chrysanthemum cardiovascular story that connects to actual human research, and it is worth following honestly — including to its limits.

Chlorogenic acid is usually the most abundant phenolic in chrysanthemum flowers, and it has been studied in humans in its own right, mostly in the context of coffee and of green-coffee-bean extracts. There are small randomized trials of chlorogenic acid supplementation reporting modest blood-pressure reductions, and a body of work on chlorogenic acid, glucose handling and endothelial function. A 2024 meta-analysis (Samavat et al., Diabetes & Metabolic Syndrome) pooled 10 randomized trials of green coffee bean extract with 563 people: systolic blood pressure fell by about 2.95 mmHg and diastolic by about 2.15 mmHg, with larger effects in people with high blood pressure, no effect on blood pressure in women, and no significant change in heart rate. No link to the dose or the length of treatment was found. The literature is searchable on PubMed.

Four reasons this does not transfer to chrysanthemum tea:

  1. Dose. The human chlorogenic acid trials generally use supplemental doses in the hundreds of milligrams per day. A cup of chrysanthemum tea supplies a small fraction of that. A cup of coffee supplies considerably more chlorogenic acid than a cup of chrysanthemum tea does.
  2. Trial quality. Much of the green-coffee-extract literature is small, industry-linked and of mixed quality, and the field has a history of retracted or discredited work. It is not a firm foundation to lean a second claim on.
  3. Matrix. An isolated compound in a capsule and the same compound in a floral infusion alongside dozens of others are not interchangeable.
  4. Nobody has closed the loop. There is no study giving people chrysanthemum tea and measuring blood pressure. Reasoning from "chrysanthemum contains chlorogenic acid" plus "chlorogenic acid supplements may lower blood pressure (BP) slightly" to "chrysanthemum tea lowers blood pressure" is inference across two unbridged gaps.

The fair summary: chlorogenic acid is the most promising constituent of chrysanthemum from a cardiovascular standpoint, and the promise belongs to the compound at supplemental doses, not to the tea. If chlorogenic acid intake is what you are after, coffee is a far larger dietary source.

Lipids, Platelets and Endothelial Function

Evidence tier: preliminary (animal and in vitro) for all of the following.

Reading this literature usefully means noticing what is absent: chrysanthemum tea is cheap, safe for most people, universally available and easy to administer. Its human intermediate-outcome studies — brachial flow-mediated dilation, ambulatory blood pressure, lipid panels — would be inexpensive and straightforward to run. Nobody has run them, which is best explained by the absence of a commercial sponsor rather than by any negative result.

The Sugar in the Can Is the Real Cardiovascular Variable

This section is short and it is the most cardiovascularly relevant thing on the page.

The overwhelming majority of chrysanthemum tea consumed worldwide is sweetened, ready-to-drink, canned or bottled. It is standard convenience-store stock across East and Southeast Asia. Many of these products contain sugar at soft-drink concentrations — commonly in the region of 20–30 g per serving, sometimes more.

Sugar-sweetened beverage intake has a substantial human epidemiological literature associating it with weight gain, type 2 diabetes, hypertension and cardiovascular disease — a body of evidence incomparably stronger than anything in the chrysanthemum literature. So for a reader drinking two or three sweetened cans a day for their heart, the net cardiovascular effect is plausibly negative, and it is driven entirely by the sugar.

The difference shows on the label: flowers brewed at home contain no added sugar, and canned versions list theirs. Unsweetened, or lightly sweetened at home, chrysanthemum tea is a pleasant zero-calorie caffeine-free drink and an alternative to a soft drink — which is, ironically, the largest genuine cardiovascular benefit available from this plant, and it comes from what the tea displaces rather than from what it contains.

Medication Interactions and Who the Research Raises Concerns For

No clinically significant drug interaction with chrysanthemum tea has been documented in humans, largely because nobody has looked. The theoretical considerations worth knowing:

The Verdict

Chrysanthemum tea is a drink, not a tested cardiovascular treatment: it has never been studied as a substitute for blood-pressure medication or home monitoring, and the sugar in a sweetened can undoes the whole argument.

Key Research Papers

Named papers link to their PubMed record; the topic searches below them show the wider literature.

  1. Han AR and colleagues, “Phytochemical composition and antioxidant activities of two different color chrysanthemum flower teas”, Molecules (2019) — the flowers analysed as a tea, with cultivars distinguished. The single most useful paper for knowing what is in your cup. PubMed PMID: 30658439
  2. Han AR and colleagues, “Quantification of antioxidant phenolic compounds in a new chrysanthemum cultivar by high-performance liquid chromatography with diode array detection and electrospray ionization mass spectrometry”, International Journal of Analytical Chemistry (2017). PubMed PMID: 28630625
  3. Liu Y and colleagues, “Chrysanthemum morifolium as a traditional herb: a review of historical development, classification, phytochemistry, pharmacology and application”, Journal of Ethnopharmacology (2024) — the comprehensive species review, including the cardiovascular pharmacology. PubMed PMID: 38621465
  4. Zou P, “Traditional Chinese medicine, food therapy, and hypertension control: a narrative review of Chinese literature”, American Journal of Chinese Medicine (2016) — context for the traditional blood-pressure indication, and a fair illustration of how weak the underlying evidence is. PubMed PMID: 27852126
  5. Zhang ZJ and colleagues, “Review of polysaccharides from Chrysanthemum morifolium Ramat.: extraction, purification, structural characteristics, health benefits, structural-activity relationships and applications”, International Journal of Biological Macromolecules (2024). PubMed PMID: 39179070
  6. Ellis LR and colleagues, “A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers”, Nutrition Reviews (2022) — 17 trials; systolic blood pressure 7.10 mmHg lower than placebo. PubMed PMID: 34927694
  7. Norouzzadeh M and colleagues, “Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: an overview of reviews and updated dose-response meta-analysis”, Complementary Therapies in Medicine (2025) — 26 trials, 1,797 people. PubMed PMID: 39870328
  8. Samavat S and colleagues, “The effects of green coffee bean extract on blood pressure and heart rate: a systematic review and dose-response meta-analysis of randomized controlled trials”, Diabetes & Metabolic Syndrome (2024) — 10 trials, 563 people. PubMed PMID: 39368321

PubMed Topic Searches

  1. Chrysanthemum and blood pressure in randomized human studies — run this yourself. The emptiness of the result set is the finding this page rests on. PubMed topic search.
  2. Hibiscus sabdariffa and blood pressure — randomized trials and meta-analyses. The contrast case: what a floral tea's evidence looks like when trials have actually been done. PubMed topic search.
  3. Chlorogenic acid and blood pressure in humans — the one chrysanthemum constituent with human trial data, at supplemental doses the tea does not deliver. PubMed topic search.
  4. Antioxidant supplement trials and mortality — the large randomized literature that ended the simple antioxidant hypothesis, including the beta-carotene and vitamin E results. Essential calibration for any "high antioxidant" claim. PubMed topic search.
  5. Limitations of in-vitro antioxidant capacity assays — why DPPH, ORAC and FRAP values do not predict health outcomes, and why the USDA withdrew its ORAC database. PubMed topic search.
  6. Polyphenol bioavailability and metabolism — glucuronidation, sulphation, colonic microbial metabolites, and achievable plasma concentrations. The gap between the cell dish and the cup. PubMed topic search.
  7. Luteolin and apigenin cardiovascular pharmacology — vasorelaxation, endothelial and anti-inflammatory mechanisms, all preclinical. PubMed topic search.
  8. Sugar-sweetened beverages and cardiometabolic risk — the large human literature that makes the canned version's sugar the dominant variable. PubMed topic search.
  9. Licorice, glycyrrhizin and blood pressure — relevant because licorice is a common chrysanthemum blending partner and is the ingredient in that blend with a real pressor effect. PubMed topic search.

Connections


Safety and disclaimer. This article is educational and is not medical advice. Chrysanthemum's antioxidant and cardiovascular claims rest on analytical chemistry and preclinical work; no randomized controlled trial shows that chrysanthemum tea lowers blood pressure, improves lipids or reduces cardiovascular risk in humans. No herbal tea has been shown to replace prescribed antihypertensive, antidiabetic or anticoagulant medication, home blood-pressure monitoring or medical follow-up. Chrysanthemum is an Asteraceae plant — the allergy and safety page covers the cross-reactions for people allergic to ragweed, mugwort, chamomile, feverfew, marigold or arnica. Pyrethrum is the insecticide plant, not a tea, and flowers of unknown species carry the risk of being the wrong plant. Concentrated chrysanthemum extracts have no established dose and no human data, and none of the research on this page studied chrysanthemum in pregnancy or breastfeeding.

Back to Table of Contents